A diverse panel of clinical acinetobacter baumannii for research and development

Madeline R. Galac, Erik Snesrud, Francois Lebreton, Jason Stam, Michael Julius, Ana C. Ong, Rosslyn Maybank, Anthony R. Jones, Yoon I. Kwak, Kate Hinkle, Paige E. Waterman, Emil P. Lesho, Jason W. Bennett, Patrick Mc Gann*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

35 Scopus citations


Over the past two decades, Acinetobacter baumannii has emerged as a leading cause of nosocomial infections worldwide. Of particular concern are panresistant strains, leading the World Health Organization (WHO) to designate carbapenem-resistant A. baumannii as a priority 1 (critical) pathogen for research and development of new antibiotics. A key component in supporting this effort is accessibility to diverse and clinically relevant strains for testing. Here, we describe a panel of 100 diverse A. baumannii strains for use in this endeavor. Whole-genome sequencing was performed on 3,505 A. baumannii isolates housed at the Multidrug-Resistant Organism Repository and Surveillance Network. Isolates were cultured from clinical samples at health care facilities around the world between 2001 and 2017. Core-genome multilocus sequence typing and high-resolution single nucleotide polymorphism (SNP)-based phylogenetic analyses were used to select a final panel of 100 strains that captured the genetic diversity of the collection. Comprehensive antibiotic susceptibility testing was also performed on all 100 isolates using 14 clinically relevant antibiotics. The final 100-strain diversity panel contained representative strains from 70 different traditional Pasteur scheme multilocus sequence types, including major epidemic clones. This diversity was also reflected in antibiotic susceptibility and antimicrobial resistance (AMR) gene content, with phenotypes ranging from pansensitive to panresistant, and over 100 distinct AMR gene alleles identified from 32 gene families. This panel provides the most diverse and comprehensive set of A. baumannii strains for use in developing solutions for combating antibiotic resistance. The panel and all available metadata, including genome sequences, will be available to industry and academic institutions and federal and other laboratories free of charge.

Original languageEnglish
Article numbere00840
JournalAntimicrobial Agents and Chemotherapy
Issue number10
StatePublished - Oct 2020
Externally publishedYes


  • Acinetobacter baumannii
  • Antimicrobial resistance
  • Drug development


Dive into the research topics of 'A diverse panel of clinical acinetobacter baumannii for research and development'. Together they form a unique fingerprint.

Cite this